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Abstract
Background: Methicillin resistant Staphylococcus aureus (MRSA) is a major human pathogen associated with
nosocomial and community infections. Panton Valentine leukocidin (PVL) is considered one of the important
virulence factors of S. aureus responsible for destruction of white blood cells, necrosis and apoptosis and as a
marker of community acquired MRSA. This study was aimed to determine the prevalence of PVL genes among
MRSA isolates and to check the reliability of PVL as marker of community acquired MRSA isolates from Western
Nepal.
Methods: A total of 400 strains of S. aureus were collected from clinical specimens and various units (Operation
Theater, Intensive Care Units) of the hospital and 139 of these had been confirmed as MRSA by previous study.
Multiplex PCR was used to detect mecA and PVL genes. Clinical data as well as antimicrobial susceptibility data
was analyzed and compared among PVL positive and negative MRSA isolates.
Results: Out of 139 MRSA isolates, 79 (56.8 %) were PVL positive. The majority of the community acquired MRSA
(90.4 %) were PVL positive (Positive predictive value: 94.9 % and negative predictive value: 86.6 %), while PVL was
detected only in 4 (7.1 %) hospital associated MRSA strains. None of the MRSA isolates from hospital environment
was found positive for the PVL genes. The majority of the PVL positive strains (75.5 %) were isolated from pus
samples. Antibiotic resistance among PVL negative MRSA isolates was found higher as compared to PVL positive
MRSA.
Conclusion: Our study showed high prevalence of PVL among community acquired MRSA isolates. Absence of
PVL among MRSA isolates from hospital environment indicates its poor association with hospital acquired MRSA
and therefore, PVL may be used a marker for community acquired MRSA. This is first study from Nepal, to test PVL
among MRSA isolates from hospital environment.
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Background
Staphylococcus aureus is one of the most common and
important human pathogen associated with broad
spectrum of diseases. It is a major cause of hospital ac-
quired infection of surgical wounds and infections asso-
ciated with indwelling medical devices. Increasing drug
resistance among S. aureus and the spread of methicillin
resistant Staphylococcus aureus (MRSA) are global
threat. The resistance of MRSA to β-lactam antibiotics is
associated with penicillin-binding protein 2a, encoded
by the mecA gene. The pathogenicity of S. aureus is
related to a number of virulence factors that allow the
organism to adhere, avoid the immune system and cause
harmful effects to the host. One of the important
cytotoxins produced by some strains of S. aureus is
the Panton Valentine leukocidin (PVL), encoded by
two genes, lukS- PV and lukF-PV [1]. The Panton
Valentine leukocidin was named after Sir Philip Noel
Panton and Francis Valentine who associated it with
soft tissue infections in 1932 [2, 3]. It is a member of
the synergohymenotropic toxin family that induces
pores in the membranes of cells.
Panton Valentine leukocidin producing MRSA usually
cause mild skin or soft tissue infections, however, severe
cases of necrotizing pneumonia and sepsis have also
been reported [4]. Panton Valentine leukocidin is present
in majority of community associated MRSA isolates and
rarely present in hospital isolates, therefore it is recog-
nized as marker of community acquired strains [5].
Epidemiological data suggest that high virulence of com-
munity acquired MRSA is associated with PVL genes
but direct evidence of association of PVL to pathogen-
esis has been limited [6]. The prevalence of PVL genes
among MRSA isolates has not been adequately reported
from Nepal. This study was planned to investigate the
prevalence of PVL genes among community and hos-
pital- acquired MRSA isolates and to compare drug
resistant pattern of PVL positive and PVL negative iso-
lates. Isolates obtained from samples collected from the
hospital environment including intensive care units were
also included in this study in order to compare the asso-
ciation of PVL with MRSA isolates associated to the
hospital environment.
Methods
This prospective study was conducted at Microbiology
laboratory of Manipal Teaching Hospital, Pokhara,
Nepal, from September 2012 to August 2013. A total of
400 isolates of S. aureus had been collected in previous
study [7] and 139 of these isolates had been confirmed
as MRSA by susceptibility testing and PCR. These iso-
lates were obtained from clinical specimens of various
departments of the hospital (Surgery, Medicine, Inten-
sive Care Units, Post-operative, Burn, Pediatric and Ear
Nose Throat units). Isolates obtained from environmen-
tal samples collected from operation theaters and Inten-
sive care units (ICU) were also included.
Isolation and identification of the isolates was per-
formed by standard methods [8]. Antibiotic susceptibility
testing was performed by Kirby-Bauer disc diffusion
method [9] in previous study and data obtained was
used for analysis. Minimal inhibitory concentration
(MIC) of vancomycin was performed to rule out the
possibility of vancomycin resistant Staphylococcus aureus
(VRSA) and vancomycin intermediate Staphylococcus aur-
eus (VISA) following CLSI guidelines [8]. Staphylococcus
aureus showing resistance to at least one agent from three
or more antimicrobial categories are labelled as multidrug
resistant [10].
Hospital and community associated S. aureus iso-
lates were categorized based on the following criteria:
Isolates cultured from clinical specimens that were
obtained after 72 h of admission of the patients or
from patients with a history of hospitalization within
6 months were considered as hospital-acquired S.
aureus strains; Isolates which were cultured within
72 h of hospitalization, from outpatient department
(OPD) or patients with no history of hospitalization
within 6 months were categorized as community- ac-
quired strains. The clinical information on the pa-
tients’ clinical background which was used to set the
criteria for classification of community and hospital
acquired MRSA was obtained from the medical
records.
Detection of mecA and PVL genes by multiplex PCR
DNA was extracted from the MRSA isolates by chloro-
form: phenol extraction method as described by Sambrook
et al. [11]. The primers used for mecA gene were MecA1
(5′-GTA GAA ATG ACT GAA CGT CCG ATA A) and
MecA2 (5′-CCA ATT CCA CAT TGT TTC GGT CTA
A) as described earlier by Geha et al. [12]. Primers used for
detection of PVL genes were Luk-PV-1 (ATC ATT AGG
TAA AAT GTC TGG ACA TGA TCC A) and Luk-PV-2
(GCATCA AGT GTATTG GATAGC AAA AGC) which
amplify a 433 base pair fragment specific for lukS/F –PV
genes, encoding the PVL S/F bicomponent proteins as de-
scribed by McClure et al. [13]. The DNA thermocycler was
programmed for initial denaturation at 94 °C for 4 min;
30 cycles of amplification (denaturation at 94 °C for 45 s,
annealing at 56 °C for 45 s, and extension at 72 °C for
30 s); and a final extension at 72 °C for 2 min. To visualize,
10 μl of the PCR amplicon was loaded with dye in 1.2 %
agarose gel containing ethidium bromide followed by elec-
trophoresis at 100 V for 1 h and visualized by using UV
transillumination at 310 nm. Fragments of DNA 310 bp
corresponded with mecA gene and 433 bp corresponded
amplification of a fragment to the PVL genes.
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Data analysis
Data was analyzed by using Pearson’s Chi-square test. A
p-value of <0.05 was considered statistically significant.
Results
A total of 139 MRSA isolates from various clinical speci-
mens were included in this study. Out of these, 35.2 %
(49/139) were HA-MRSA, 59.7 % (83/139) were CA-
MRSA and 5 % (7/139) were from hospital environment.
The genes mecA (310 bp) and PVL (433 bp) were
detected by multiplex PCR (Fig. 1). MecA and PVL
genes were detected in 79/139 (56.8 %) of the isolates.
The majority of the PVL positive isolates were obtained
from pus samples accounting for 74/98 (75.5 %). The
remaining sample types showed lower percentage of
PVL genes whereas among the MRSA from hospital en-
vironment samples, none of the isolates were found
positive for PVL (Table 1).
The results of antimicrobial susceptibility testing of
139 isolates are shown in Table 2. Our analysis could
not find any statistically significant differences in the
susceptibility pattern of PVL positive and PVL negative
isolates except towards erythromycin. Seventy three per-
cent (102/139) MRSA were multidrug resistant; 50 were
PVL positive while 52 were PVL negative. Among the 79
PVL positive isolates, 63.3 % (50/79) were MDR, while
this percentage was found significantly higher 86.6 %
(52/60) among PVL negative isolates (p value: <0.005).
Among 37 MRSA isolates which were non MDR, 29
(78.4 %) were PVL positive and 8 (21.6 %) were PVL
negative. The difference between PVL positive non MDR
and PVL positive MDR MRSA was statistically signifi-
cant (p value <0.001).
Out of the 139 MRSA isolates, 56 (40.3 %) were found
to be hospital associated MRSA and the remaining 83
(59.7 %) isolates were community associated MRSA by
above mentioned clinically based criteria. Among the
83 CA-MRSA, 75 (90.4 %) were PVL positive while
only 7.1 % (4/56) HA-MRSA were PVL positive (p
value <0.001). All seven MRSA isolates obtained from
environmental samples were negative for PVL.
Discussion
Global emergence of MRSA is serious public health
problem and challenge to clinicians. A number of factors
contribute to the pathogenicity and drug resistance of S.
aureus. The first PVL positive MRSA was observed in
the late 1990 and these strains have become globally
distributed in the recent years [14]. The role of PVL in
enhancing virulence of S. aureus and their pathogenicity
is being debated. Panton Valentine leukocidin increases
the pathogenicity of S. aureus by necrosis, accelerating
apoptosis and destruction of polymorphonuclear and
mononuclear cells thereby contributing to morbidity and
mortality [15]. However, some studies have shown no
association of PVL with the virulence of the organism by
demonstrating better clinical outcome of skin and soft
tissue infections [16, 17]. Therefore, the role of PVL in
clinical outcome is still debated. The reason for the re-
sults in clinical outcomes in these studies could be influ-
enced by the effectiveness of antibiotic treatment
applied.
Panton Valentine leukocidin is commonly used as a
marker for community acquired MRSA, responsible
for soft-tissue and deep dermal infections [18, 19].
However, the global scenario of PVL among MRSA
isolates varies.
Reports from various countries show the increasing
prevalence of PVL among MRSA isolates [20, 21]. Sub-
arna Roy et al. from India, have reported overall 62.85 %
of PVL prevalence among MRSA and MSSA (MRSA:
85.1 % and MSSA: 48.8 %) which indicates a higher
prevalence among MRSA than our findings [22]. Similar
study by D’Souza et al. from Mumbai, India, reported
prevalence of 64 % PVL positive isolates among MRSA
[23]. A lower prevalence of PVL has been reported from
other parts of world (5 % in France, 4.9 % in UK, 8.1 %
in Saudi Arabia and 14.3 % in Bangladesh) [15, 24–26],
Fig. 1 Multiplex PCR for mecA (310 bp) and PVL (433 bp) genes. M: Marker (100 bp), 1: Negative control, 2: Positive control, 3–8: Test isolates
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reflecting that the prevalence of PVL varies greatly be-
tween geographical locations and populations.
This study analyzes the role of PVL in infections at
different sites. Skin and soft tissue infections are pre-
dominantly (75.5 %) caused by PVL producing organ-
isms as the leucocidal activity of PVL provides survival
advantage to the bacteria. The association of PVL with
isolates from other specimens was less. Presence of PVL
in deep seated infections like blood stream infections
was found less common in our study indicating poor
association of PVL with invasiveness of MRSA.
The results of antimicrobial susceptibility testing re-
vealed higher resistance among PVL negative MRSA
isolates as compared to PVL positive MRSA isolates,
however the differences were not statistically significant
except in case of erythromycin (Table 2). Similar finding
was observed in case of clindamycin and tetracycline in
another study from Nepal [27].
Similarly, the percentage of MDR MRSA among PVL
negative (86.6 %) isolates was found significantly higher
than in PVL positive (63.3 %) isolates (p value <0.005).
These findings suggest that PVL is probably not associ-
ated with MDR phenotypes in this study. Similarly, a
significantly higher prevalence of PVL was observed
among non MDR MRSA.
Association of PVL among male patients was found
slightly higher (54 %) than female (46 %) patients.
Higher prevalence of PVL among children (<14 years
of age) was observed as compared to adults and old
age group patients, although difference was statisti-
cally insignificant. Similar findings were observed in
another study from India [28]. However, some studies
have reported strong association of PVL among
young children [29]. The highest number (65/79) of
PVL-MRSA were isolated from the patients of sur-
gery department, followed by the burn units (5/79),
the orthopedic unit (5/79), and other departments
(4/79). Similar distribution of PVL positive MRSA
isolates in various units of hospital was reported
from India [28].
PVL was considered as important marker for differen-
tiation of HA-MRSA and CA-MRSA. In our study, 75
out of 83 CA-MRSA isolates were found PVL positive
with positive predictive value 94.9 % and negative pre-
dictive value 86.6 %. However, some studies have shown
association of PVL genes among HA- MRSA isolates
also [27, 28]. Most of the studies including our study
categorized HA-MRSA and CA-MRSA based upon the
history of the patient or by getting information from
medical record. However, information obtained from
patient or from medical record may not be reliable all
the time. To overcome this, we for the first time from
Nepal, tested seven isolates of MRSA obtained from the
environment of various units of the hospital including
wards and intensive care units. As these isolates are not
known to be related to the specimen from patients and
isolated from hospital environment, we considered them
as presumptive hospital strains. These seven isolates
were found negative for PVL genes which could indicate
that PVL is not normally found in the isolates of hospital
environment. However, these isolates are not necessarily
representative of hospital environment in general.
Absence of PVL in S. aureus from inanimate objects of
hospital environment may indicate limited role of antil-
eucocytic activity outside the host. In our study, we
found association of PVL gene in four MRSA isolates
which are hospital acquired as per the clinical criteria
described above. As the majority of PVL positive
strains represent community isolates, this shows that
the criteria set for this study might have limitations
and/or these isolates could have been originated from
out patients and transmitted to health care workers
and patients. To our knowledge, it is likely that these
four PVL positive isolates might have been recently
transmitted from a community source to hospital set-
tings. In contrast, another study from Nepal reported
higher prevalence of PVL among nosocomial MRSA
isolates [27].
Limitation of the study: SCCmec typing was not
performed in the current study but is planned to be
pursued in further studies.
Table 2 Antibiotic resistance pattern of PVL positive and PVL
negative MRSA isolates
Antibiotic PVL positive MRSA
(n = 79) Frequency (%)
PVL negative MRSA
(n = 60) Frequency (%)
P value
Penicillin 79 (100 %) 60 (100 %) –
Erythromycin 52 (65.8 %) 50 (83.3 %) 0.021a
Ciprofloxacin 61 (77.2 %) 51 (85 %) 0.251
Cotrimoxazole 48 (60.7 %) 45 (75 %) 0.077
Gentamicin 34 (43 %) 32 (53.3 %) 0.229
Clindamycin 08 (10.1 %) 07 (11.6 %) 0.772
Amikacin 06 (7.6 %) 08 (13.3 %) 0.266
Tetracycline 04 (5 %) 06 (10 %) 0.265
Vancomycin 00 00 –
aSignificant association
Table 1 Distribution of PVL genes among MRSA isolates in
different specimens
Specimen type Total number of MRSA PVL positive (%)
Pus 98 74 (75.5 %)
Blood 14 2 (14.3 %)
Urine 12 2 (16.6 %)
Sputum 6 1 (16.6 %)
Hospital environment 7 0
Body fluids 2 0
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Conclusion
The prevalence of the PVL among the MRSA isolates in
this study was found relatively high especially among
pus samples which indicate a possible key role of PVL in
pathogenesis of pyogenic infections especially skin and
soft tissue infections in community setting. The PVL
positive MRSA isolates showed higher sensitivity against
antibiotics as compared to PVL negative isolates indicat-
ing that PVL is not associated with drug resistance
mechanisms. The presence of PVL among multi drug
resistant bacteria like MRSA may be involved in viru-
lence and increase the challenges for clinicians. As
expected, the majority of PVL positive MRSA were
community-associated isolates, whereas only four MRSA
from hospital related cases were found positive for PVL.
No PVL was detected in MRSA isolated from the hos-
pital environment. In our view, the presence of PVL can
be used as a reliable marker for CA-MRSA in these
resource limited settings in Nepal.
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